PF-05280586, a biosimilar for rituximab (Rituxan/MabThera), delivered positive top-line results in the phase III REFLECTIONS B3281006 follicular lymphoma (FL) trial, meeting its primary endpoint for overall response rate (ORR).
In September 2017, the FDA accepted a biologics license application for the rituximab biosimilar Rixathon (GP2013), which is manufactured by Sandoz (Novartis). Also in September 2017, the FDA approved ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), as the first FDA-approved biosimilar for the treatment of patients with cancer. In December 2017, the FDA approved the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst).
- FDA Approves Two New Indications for Rituxan in Patients With Non-Hodgkin's Lymphoma. Genentech. Published: September 29, 2006. Accessed: January 24, 2018. http://bit.ly/2Dwmykl.
- Rituximab Full Prescribing Information. Accessed: January 24, 2018. http://bit.ly/2n7X5GZ.
... to read the full story